Keystone Heart
Keystone Heart Ltd 是一家医学设备公司，开发和生产脑保护装置，从而减少心血管手术中脑损伤引发的中风、神经认知退化和痴呆的风险。该公司主要注重保护大脑免受栓塞影响，减少经导管主动脉瓣置换术、外科瓣膜置换术、心房颤动消融术和其它结构性心脏手术的脑梗塞风险。创新的设备旨在帮助介入性心脏病专家、电生理学家和心外科医生在手术时保护脑储备。

Keystone Heart 致力于通过创新的技术和临床研究提高患者护理水平。TriGuard™ 脑保护装置（经导管主动脉瓣置换术）临床研究目前仍在欧洲、加拿大和巴西进行。

Keystone Heart 与知名的介入性心脏病专家、心外科医生和神经专家展开了合作。

该公司的管理层在介入性心脏病学和医学设备方面拥有广泛的经验。

Keystone Heart 于2004年成立，总部位于以色列，由 OrbiMed Advisors LLC 和 OrbiMed Israel Partners 资助。该公司拥有和保持了广泛的知识产权组合，并且获得了 ISO 认证。

Keystone Heart Ltd is a medical device company developing and manufacturing cerebral protection devices to reduce the risk of stroke, neurocognitive decline and dementia caused by brain damage associated with cardiovascular procedures. The Company is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, surgical valve replacement, atrial fibrillation ablation and other structural heart procedures. Novel devices are designed to help interventional cardiologists, electrophysiologists and cardiac surgeons to preserve brain reserve while performing these procedures.
Keystone Heart is dedicated to advancing patient care through innovative technology and clinical research. Clinical studies with the TriGuard™ Cerebral Protection Device (TAVR procedures) are currently ongoing in Europe, Canada and Brazil.

Keystone Heart collaborates with renowned interventional cardiologists, cardiac surgeons and neurologists.
The Company’s management has extensive experience in the fields of interventional cardiology and medical devices.

Founded in 2004 and headquartered in Israel, Keystone Heart is funded by OrbiMed Advisors LLC and OrbiMed Israel Partners. The Company holds and maintains a comprehensive IP portfolio and is ISO certified.